SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major talking point following its recent earnings report, which, despite beating on revenue and EPS, presented cautious forward guidance and a decision to pause share buybacks. This has ignited community debate, with many investors split between seeing a massive 'buy the dip' opportunity and expressing concern over slowing growth and the financial implications of a potential Warner Bros. Discovery acquisition. The discussion reflects a mixed outlook on whether strategic shifts will accelerate long-term value or introduce short-term headwinds.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending after CEO Ryan Cohen and another board member significantly increased their stakes in the company through recent share purchases. This insider buying has ignited a strong bullish sentiment among investors, who are actively discussing the potential for a short squeeze and viewing the moves as a vote of confidence. The stock's resilience amidst broader market volatility further fuels community speculation about future catalysts.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to recent positive Phase 1 clinical trial data for its eczema treatment, soquelitinib, which demonstrated strong efficacy and a favorable safety profile, initially fueling a significant surge in interest. This positive momentum is now tempered by a proposed $150 million public offering, sparking a community debate between those who see it as a strategic capital raise for a potentially breakthrough oral therapy and those concerned about dilution for an early-stage drug.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a significant downturn, with many in the community attributing the "brutal day" to broader geopolitical tensions and proposed tariffs. Traders are hotly debating whether the stock's historically oversold RSI levels present a "buy the dip" opportunity ahead of its upcoming earnings report or if further declines are imminent due to perceived stagnation in AI innovation.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending following its strategic acquisition of Australian Strategic Materials and a highly positive feasibility study for expanding rare earth processing capabilities. The community is actively discussing the company's pivotal role in bolstering the U.S. domestic supply chain for critical minerals, driven by surging demand for nuclear energy and materials vital for AI and defense technologies.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing significant volatility as former President Trump's strong stance on Greenland and related tariff threats generate global market uncertainty, prompting a shift away from U.S. assets. The community is split, with many anticipating a rapid rebound for tech stocks while others warn of a deeper correction driven by these geopolitical tensions and broader concerns about AI's market impact.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding Ltd. is actively discussed following its announcement to acquire a wine authentication and trading business, a strategic move to diversify into luxury products. This development, however, coincides with a public offering of units, leading to significant price fluctuations. Community sentiment is divided between those anticipating a strong rally due to the news and low float, and others cautioning against a potential "Chinese pump and dump" given the offering and historical volatility.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals is trending following robust preliminary 2025 Ojemda product revenue and optimistic 2026 guidance, alongside the recently completed acquisition of Mersana Therapeutics. The community is actively discussing significant options activity and renewed buyout speculation, as analysts upgrade ratings and view the Mersana deal as strengthening the company's pipeline and commercial prospects.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is drawing significant attention following a long-term data center leasing agreement with Riot Platforms, seen as a strategic move to secure direct AI infrastructure. This development, combined with strong analyst conviction in AMD's growing AI market share and its impressive resilience during broader market weakness, is fueling active community discussion about its promising long-term trajectory.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending strongly as escalating geopolitical tensions, particularly surrounding U.S.-Europe tariff threats over Greenland, drive a significant risk-off sentiment across markets. The community is actively discussing gold's role as a premier safe haven, pushing prices to new highs amidst global instability and concerns over economic and financial system shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regencell Bioscience (NASDAQ:RGC) Trading Down 7.8% - What's Next?

Regencell Bioscience (NASDAQ:RGC) Trading Down 7.8% - Here's What Happened...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Should You Sell?

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Time to Sell...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Here's What Happened

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Still a Buy...

<ul class="summary-bullets"><li>Regencell stated in an October SEC filing that it may be required to curtail or discontinue its operations in the future.</li><li>In the 2025 and 2024 fiscal years, Regencell reported a net loss of $3.58 million and $4.36 million, respectively.</li><li>The company had indicated that it anticipates incurring additional losses before realizing any revenues.</li></ul>Shares of Regencell Bioscience Holdings (RGC) have been drawing significant investor attention after gaining nearly 152% in the first four trading sessions of 2026.Following Wednesday’s relentless rally, the shares continued to climb in Thursday’s pre-market trade as well, rising by over 20% at the time of writing.While the bulk of the recent surge has come in 2026, RGC stock is still up nearly 218% since October 31, despite the company flagging a “substantial doubt” about its ability to continue as a going concern.<figure class="image"><img src="https://news.stocktwits-cdn.com/RGC_stock_chart_jpg_b4d92bf445.webp" alt="RGC stock performance from Jan. 1, 2025 to Jan. 7, 2025" width="1516" height="417"><figcaption>RGC stock performance from Jan. 1, 2025 to Jan. 7, 2025 | Koyfin</figcaption></figure><h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits regarding Regencell Bioscience was trending in the ‘bullish’ territory at the time of writing.One bullish user thinks that traders shorting the stock are in “huge trouble now.”<stembedurl>https://stocktwits.com/elbardinnyo/message/641188884</stembedurl>Another user said they treat it as a momentum-only stock.<stembedurl>https://stocktwits.com/Faniabh/message/641180065</stembedurl><h2 class="st-heading-2">RGC’s Going Concern Flag</h2>In a filing with the U.S. Securities and Exchange Commission in October 2025, the company said that there is a “substantial doubt” about its ability to continue as a going concern.It added that this indicates the company may be required to curtail or discontinue its operations in the future.“If we discontinue our operations, you may lose all of your investment,” Regencell said, adding that it anticipates incurring additional losses before realizing any revenues. In the 2025 and 2024 fiscal years, Regencell reported a net loss of $3.58 million and $4.36 million, respectively.Regencell is an early-stage company focusing on research, development, and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder.<a href="https://stocktwits.com/symbol/RGC">RGC stock</a> is up 152% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-hele-stock-falling-today/cmUb4SeR4Po">HELE Stock Slides Pre-market As Tariff Headwinds Trigger FY26 Earnings Guidance Cut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

RGC Stock Gains 20% Pre-Market — Retail Says Shorts Are In ‘Huge Trouble’

Regencell shares are up nearly 218% since October 31, despite the company flagging a “substantial doubt” about its ability to continue as a going concern.

Why Is RGC Stock Soaring Today?

Equity

Regencell Bioscience (NASDAQ:RGC) Stock Price Up 14.6% - Time to Buy?

Regencell Bioscience (NASDAQ:RGC) Trading 14.6% Higher - What's Next...

Regencell Bioscience (NASDAQ:RGC) Sees Strong Trading Volume - Here's Why

Regencell Bioscience (NASDAQ:RGC) Sees Unusually-High Trading Volume - Should You Buy...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Still a Buy?

Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - What's Next...

Regencell Bioscience (NASDAQ:RGC) Trading 5.2% Higher - Time to Buy?

Regencell Bioscience (NASDAQ:RGC) Trading 5.2% Higher - Here's What Happened...

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Here's What Happened

Regencell Bioscience (NASDAQ:RGC) Shares Gap Down - Should You Sell...

Regencell Bioscience (NASDAQ:RGC) Trading Down 8.3% - Time to Sell?

Regencell Bioscience (NASDAQ:RGC) Trading Down 8.3% - Here's What Happened...

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

RGC
Regencell Bioscience Holdings Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RGC News

RGCRegencell Bioscience Holdings Ltd